India  

'COVAXIN' demonstrated efficacy of 80.6% in Phase 3 clinical trial: Bharat Biotech

Video Credit: ANI - Duration: 01:42s - Published
'COVAXIN' demonstrated efficacy of 80.6% in Phase 3 clinical trial: Bharat Biotech

'COVAXIN' demonstrated efficacy of 80.6% in Phase 3 clinical trial: Bharat Biotech

Bharat Biotech's COVID-19 vaccine, 'COVAXIN' has demonstrated an interim vaccine efficacy of 80.6% in its Phase 3 clinical trial.

"Today is an important day for us, country and Indian science.

COVAXIN has demonstrated an interim vaccine efficacy of around 80.6% in its Phase 3 clinical trial.

The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with ICMR," Bharat Biotech chairman Dr Krishna Ella.


You Might Like


💡 newsR Knowledge: Other News Mentions

BBV152 BBV152 Vaccine against COVID-19

Honest thieves 'return' coronavirus vaccine with apology in Haryana

As per the police, the thieves took away 1,710 doses of Covishield and Covaxin from the storeroom of the Civil Hospital.
DNA
1710 doses of COVID vaccine stolen in Haryana's Jind [Video]

1710 doses of COVID vaccine stolen in Haryana's Jind

1710 doses of COVID-19 vaccine including 1270 of Covishield and 440 of Covaxin and files were stolen from PPC centre at Civil Hospital in Jind in Haryana. Deputy CMO of Jind, Dr Ramesh Panchal said, "I'll also check our main store that keeps supply for entire district. I'll also inform officials." Police started investigation in the matter and said, "The video footage shows two people committing the crime. We are investigating the matter."

Credit: ANI    Duration: 03:27Published

COVID-19: 1,710 doses of Covishield and Covaxin stolen from Jind civil hospital

A total of 1,270 doses of Covishield and 440 of Covaxin were stolen from the hospital, SHO of Civil Lines police station Rajender Singh said.
DNA

‘Covaxin efficacy 78%, works against variants’

Indigenous Covid-19 vaccine Covaxin has shown an overall interim clinical efficacy of 78% in fighting Covid-19. It has also shown 100% efficacy against severe..
IndiaTimes

COVID-19 COVID-19 Disease caused by severe acute respiratory syndrome coronavirus 2

Frontline California health care worker dies of Covid [Video]

Frontline California health care worker dies of Covid

CNN’s Jake Tapper reports.

Credit: Bleacher Report AOL    Duration: 00:25Published
Odisha's steel plant dispatches 20 tonnes oxygen to Visakhapatnam [Video]

Odisha's steel plant dispatches 20 tonnes oxygen to Visakhapatnam

20 tonnes oxygen was dispatched from Odisha's JSPL steel plant, located in Angul, to Visakhapatnam under police escort. Loading was carried out in presence of police staff. Amid surge in COVID cases, several states are facing oxygen shortage.

Credit: ANI    Duration: 01:01Published
Moradabad man disguised as 'Sai Baba' creates awareness about COVID [Video]

Moradabad man disguised as 'Sai Baba' creates awareness about COVID

A man in Moradabad, dressed as Sai Baba, is creating awareness among people to follow COVID guidelines and wear masks. Every Thursday, Vipin Kumar stands outside a temple in his locality with a banner in his hand asking people to wear masks. He said, "I don't allow people to enter the temple without masks, if they don't have I give them masks."

Credit: ANI    Duration: 01:34Published
Ro-Ro express train carrying liquid oxygen leaves RINL Vizag steel plant [Video]

Ro-Ro express train carrying liquid oxygen leaves RINL Vizag steel plant

Amid surge in COVID cases, shortage of oxygen was reported by several states. Ro-Ro express train carrying liquid oxygen moved out from the RINL Vizag steel plant and will be taken over by Indian Railways. The train is en route to Maharashtra, which is facing acute shortage of oxygen.

Credit: ANI    Duration: 01:13Published

Bharat Biotech Bharat Biotech Indian biotechnology company and vaccine manufacturer

Assam govt to give free COVID vaccines to everyone from 18-45 years [Video]

Assam govt to give free COVID vaccines to everyone from 18-45 years

Assam government has procure 2 crore vaccine from Serum Institute of India and Bharat Biotech and will provide free vaccines to everyone from 18 to 45 years of age, informed state Health Minister Himanta Biswa Sarma on April 21. "Government of Assam has decided to procure 2 crore vaccines, 1 crore vaccine from Serum Institute of India and another from Bharat Biotech so that we can give free vaccines to the citizen belonging to 18 to 45 years group. We want to start vaccination drive early as possible," said State Health Minister Sarma.

Credit: ANI    Duration: 01:40Published

Covaxin shows 78% overall interim efficacy, 100% efficacy against severe Covid: Bharat Biotech & ICMR

Bharat Biotech's Covaxin vaccine has shown 78% interim efficacy against the coronavirus, as per the result from phase 3 trials. The vaccine has also demonstrated..
IndiaTimes

Covid-19: Bharat Biotech ramps up Covaxin capacity to 700 million doses per annum

Bharat Biotech, the developer of indigenous Covid-19 vaccine Covaxin, on Tuesday said it has scaled up its manufacturing capacities of Covaxin to 700 million..
IndiaTimes

Centre gives nod for Rs 4,500 crore credit support for SII, Bharat Biotech to boost COVID-19 vaccine production

The financial support came as the government decided to open up vaccination for all citizens above the age of 18 from May 1.
DNA

Indian Council of Medical Research Indian Council of Medical Research Government Organization

Only 2-4 infections per 10k found in those vaccinated with two doses: ICMR

In a strong validation of the utility of vaccines in combating Covid 19, the Indian Council of Medical Research (ICMR) on Wednesday said only 2-4 per 10,000..
IndiaTimes

Covaxin neutralises double mutant strain, effective against multiple variants of SARS-CoV-2: ICMR

Bharat Biotech's Covaxin has received Emergency Use Authorizations (EUAs) for COVID-19 treatment in India and in several countries across the globe.
DNA
‘No difference in Covid death percentage between first & second wave’: ICMR D-G [Video]

‘No difference in Covid death percentage between first & second wave’: ICMR D-G

Dr Balram Bhargava, Director-General (DG) of the Indian Council of Medical Research (ICMR) said there is no change in death rate between the first and second Covid-19 wave. "There is no change in the death rate between the first wave and the second wave. Similar trends are being seen across all the states because this is a countrywide data of a national registry data which has been collected of only hospitalised patients. So this is 10,000 hospitalised patients that are being analysed,” said Bhargava. He also said that higher requirement of oxygen was found in the second wave. Watch the full video for more.

Credit: HT Digital Content    Duration: 01:57Published

Related news from verified sources

COVAXIN phase-3 results show interim efficacy of 81%: Bharat Biotech releases data

Bharat Biotech announced the phase 3 results of its coronavirus vaccine ‘Covaxin’on Wednesday...
Zee News - Published

Lancet publishes Covaxin phase 2 trials data

prestigious medical journal The Lancet has now published Phase 2 clinical trial results of Bharat...
IndiaTimes - Published


Related videos from verified sources

Mumbai's Haffkine Institute gets Centre's nod to produce Covaxin [Video]

Mumbai's Haffkine Institute gets Centre's nod to produce Covaxin

The Central Government has given permission to Haffkine Institute to produce Bharat Biotech's Covaxin. CM Uddhav Thackeray thanked PM Modi through a tweet by CM office, Maharashtra on April 15, "The..

Credit: ANI     Duration: 01:14Published
Nurses share experience after administering COVID vaccine to PM Modi [Video]

Nurses share experience after administering COVID vaccine to PM Modi

Prime Minister Narendra Modi took his second shot of COVID-19 vaccine at AIIMS, Delhi on April 08. He received the first dose of Bharat Biotech's COVAXIN on March 01. "I have given the second dose of..

Credit: ANI     Duration: 01:16Published
Phase 3 Clinical Trial Of Pfizer Covid-19 Vaccine Remains Highly Effective After Six Months [Video]

Phase 3 Clinical Trial Of Pfizer Covid-19 Vaccine Remains Highly Effective After Six Months

CBS4's Hank Tester reports on how Pfizer confirmed this week that an ongoing Phase 3 clinical trial of its coronavirus vaccine remains highly effective for at least six months after the second dose.

Credit: CBS4 Miami     Duration: 02:26Published